According to documents submitted to the SEC, medical technology company Nuwellis, Inc. announced that its board of directors has approved a 1-for-10 reverse stock split plan, which will officially take effect on June 25, 2026.

On the effective date of the reverse stock split, June 25, 2026, the company’s common shares will begin trading on the Nasdaq Capital Market under the adjusted new code. This reverse stock split is intended to raise the company’s per-share price to meet the minimum price requirement for continued listing on Nasdaq. Shareholders are not required to take any action for this reverse split. After the adjustment of the split ratio, each shareholder’s proportional ownership of the company will remain unchanged. Upon completion of the split, the company’s authorized share capital will be reduced proportionally. A reverse stock split is a common capital structure adjustment used by listed companies when the share price remains below the exchange’s requirements for an extended period. This measure is generally aimed at reshaping the market image and attracting broader institutional investor attention.